{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Respiratory+Disease&page=3",
    "query": {
      "condition": "Severe Respiratory Disease",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 938,
    "total_pages": 94,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Respiratory+Disease&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Respiratory+Disease&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T10:12:12.309Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02949843",
      "title": "Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EGFR Activating Mutation",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Stage IV Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Targeted Molecular Therapy",
          "type": "DRUG"
        },
        {
          "name": "Tyrosine Kinase Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 19,
      "start_date": "2017-03-10",
      "completion_date": "2021-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02949843"
    },
    {
      "nct_id": "NCT07615010",
      "title": "A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "agenT-797",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MiNK Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-05-26",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07615010"
    },
    {
      "nct_id": "NCT01551888",
      "title": "Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Aclidinium/formoterol 400/12μg",
          "type": "DRUG"
        },
        {
          "name": "Formoterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-01",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2017-02-14",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 1,
      "location_summary": "Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01551888"
    },
    {
      "nct_id": "NCT07219173",
      "title": "A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Brenipatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 531,
      "start_date": "2025-10-22",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 17,
      "location_summary": "Tempe, Arizona • Newport Beach, California • Northridge, California + 13 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219173"
    },
    {
      "nct_id": "NCT02038829",
      "title": "A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SUN101 3 mcg",
          "type": "DRUG"
        },
        {
          "name": "SUN-101 6.25 mcg",
          "type": "DRUG"
        },
        {
          "name": "SUN-101 12.5 mcg",
          "type": "DRUG"
        },
        {
          "name": "SUN-101 50 mcg",
          "type": "DRUG"
        },
        {
          "name": "Aclidinium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sunovion Respiratory Development Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "40 Years to 65 Years"
      },
      "enrollment_count": 96,
      "start_date": "2014-01",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2018-04-10",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 10,
      "location_summary": "Clearwater, Florida • Charlotte, North Carolina • Raleigh, North Carolina + 5 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Easley",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038829"
    },
    {
      "nct_id": "NCT05092581",
      "title": "COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "casirivimab+imdevimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Minute to 17 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-12-16",
      "completion_date": "2022-06-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 2,
      "location_summary": "Stony Brook, New York • Memphis, Tennessee",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05092581"
    },
    {
      "nct_id": "NCT00877383",
      "title": "Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Indacaterol 150 μg",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium 18 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to indacaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1142,
      "start_date": "2009-04",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2011-08-25",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 116,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00877383"
    },
    {
      "nct_id": "NCT04448145",
      "title": "Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19",
        "Corona Virus Infection",
        "SARS-CoV 2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2020-03-26",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04448145"
    },
    {
      "nct_id": "NCT00743353",
      "title": "Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Sarcoma",
        "Melanoma",
        "Lung Cancer",
        "Breast Cancer",
        "High Grade Gliomas"
      ],
      "interventions": [
        {
          "name": "F-18 RGD-K5",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Siemens Molecular Imaging",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Days and older"
      },
      "enrollment_count": 16,
      "start_date": "2008-08",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2009-02-02",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743353"
    },
    {
      "nct_id": "NCT02536508",
      "title": "Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "BGF MDI 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "GFF MDI 14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF MDI 320/9.6 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 627,
      "start_date": "2015-08-10",
      "completion_date": "2017-09-12",
      "has_results": true,
      "last_update_posted_date": "2021-02-26",
      "last_synced_at": "2026-10-11T10:12:12.309Z",
      "location_count": 64,
      "location_summary": "Dothan, Alabama • Jasper, Alabama • Peoria, Arizona + 56 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02536508"
    }
  ]
}